Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

Hims & Hers dipped 19% post-Q4 earnings. Read here for HIMS stock's growth trends, margin concerns, and why this could be a ...

Hims & Hers delivered Q4 2024 earnings that saw the stock sell off nearly 20% after hours. Find out why I rate HIMS stock a ...

Hims & Hers Health reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the ...

On Friday, the Food and Drug Administration declared the semaglutide shortage over, sending Hims & Hers shares down 26%.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

In a report released yesterday, David Larsen from BTIG maintained a Buy rating on Hims & Hers Health (HIMS – Research Report), with a price ...

Shares of Hims & Hers Health (HIMS) sank in after-hours trading after the healthcare company reported earnings for its fourth ...